Court Upholds Denial of Medical Pot Reimbursement for Psych Injury

Why It Matters

The ruling clarifies that medical cannabis is not automatically deemed reasonable for workers’ compensation, potentially curbing similar claims and influencing employer liability strategies. It underscores the clash between state‑level marijuana legalization and federal‑inspired compensation statutes.

Key Takeaways

• Delaware court upheld denial of medical marijuana reimbursement for PTSD
• Claimant failed to prove treatment was reasonable under workers' comp law
• Employer’s expert testimony outweighed claimant’s provider in decision
• Ruling may limit future workers’ comp claims for cannabis therapies
• Highlights tension between state marijuana laws and compensation statutes

Pulse Analysis

The intersection of workers’ compensation law and the expanding landscape of medical marijuana has become a flashpoint for courts across the United States. While more than 30 states have legalized cannabis for therapeutic use, compensation statutes often still require treatments to be "reasonable and necessary" under a traditional medical standard. Delaware’s Workers’ Compensation Act mirrors this approach, demanding rigorous proof that a therapy directly addresses a work‑related injury without introducing undue risk. This legal backdrop sets the stage for disputes when claimants seek reimbursement for cannabis, a substance whose clinical evidence remains mixed and whose regulatory status is still evolving.

In the Family Dollar case, the claimant suffered a severe psychological injury after a violent robbery in 2004, leading to PTSD, anxiety, and depression. She testified to daily cannabis use and cited improvements in mood and functioning, supported by a psychiatric nurse practitioner. However, the employer marshaled a neurologist, neuropsychologist, and a certified medical marijuana evaluator, who argued that the drug could exacerbate her existing seizure disorder and psychiatric symptoms. Their testimony emphasized the claimant’s extensive psychiatric history and alleged symptom exaggeration, ultimately persuading the board that she had not satisfied the statutory burden of proof. The decision illustrates how expert testimony can tip the balance in workers’ comp hearings, especially when the medical community remains divided on cannabis efficacy.

The broader implication for employers, insurers, and claimants is clear: medical marijuana will not be presumed covered under workers’ compensation without compelling, case‑specific evidence of necessity and safety. Companies may tighten their claims management protocols, requiring more stringent documentation and possibly seeking independent medical reviews. For claimants, the ruling signals a need to explore alternative, evidence‑backed therapies or to build a stronger evidentiary record when pursuing cannabis as a treatment option. As state legislatures continue to refine cannabis policies, courts will likely play a pivotal role in delineating the boundaries between lawful medical use and compensation eligibility.